US2020246430A1PendingUtilityA1

Amyloid conjugate and uses and methods thereof

51
Assignee: ARACLON BIOTECH SLPriority: Feb 15, 2016Filed: Apr 22, 2020Published: Aug 6, 2020
Est. expiryFeb 15, 2036(~9.6 yrs left)· nominal 20-yr term from priority
Inventors:Manuel Sarasa Barrio
C07K 14/4711C07K 7/06C07K 14/43504A61K 47/646C07K 2317/33C07K 16/18A61K 47/643C07K 2319/31C07K 2319/00A61K 9/06A61K 38/03A61K 47/42A61K 39/0007A61P 25/28A61K 39/39A61K 47/64C07K 16/2872C01F 7/02A61K 2039/55505A61K 38/1767C07K 14/47A61K 47/62C07K 19/00A61K 39/3955
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A composition includes aluminum hydroxide gel and a conjugate of at least one CysA13(33-40) peptide linked to the keyhole limpet hemocyanin (KLH). Maleimidobutyric acid Nhydroxysuccinimide ester (SM) serves as cross-linking agent. The composition can produce an effective and specific immune response against Aβ40. The antibodies produced are specific for Aβ40 without significantly binding to Aβ42. The composition can increase the response against Aβ40 compared with the response produced by other conjugates that include CysAβ(33-40) peptide and KLH, and are bound or conjugated by other crosslinking agents.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A composition comprising aluminum hydroxide gel and a conjugate of at least one CysAβ(33-40) peptide (SEQ ID NO: 1) linked to the keyhole limpet hemocyanin (KLH), wherein the crosslinking agent connecting each CysAβ(33-40) peptide to the keyhole limpet hemocyanin (KLH) of the conjugate is the maleimidobutyric acid Nhydroxysuccinimide ester (SM), wherein at least 45 CysAβ(33-40) peptides (SEQ ID NO: 1) is linked to each keyhole limpet hemocyanin (KLH). 
     
     
         2 . A pharmaceutical composition comprising i) a conjugate comprising at least one CysAβ(33-40) peptide (SEQ ID NO: 1) linked to keyhole limpet hemocyanin (KLH) via a crosslinking agent, and ii) an aluminum hydroxide gel, wherein the crosslinking agent connecting each CysAβ(33-40) peptide to the keyhole limpet hemocyanin (KLH) of the conjugate is maleimidobutyric acid N-hydroxysuccinimide ester (SM), and wherein a pH of the composition ranges from 5.8 to 7.0. 
     
     
         3 . The pharmaceutical composition according to  claim 2 , wherein the pH of the composition ranges from 6.2 to 7.0. 
     
     
         4 . The pharmaceutical composition according to  claim 2 , wherein the pH of the composition ranges from 5.8 to 6.2. 
     
     
         5 . The pharmaceutical composition according to  claim 2 , wherein the concentration of the at least one CysAβ(33-40) peptide (SEQ ID NO: 1) is at least 100 μg. 
     
     
         6 . The pharmaceutical composition according to  claim 2 , wherein the concentration of the at least one CysAβ(33-40) peptide (SEQ ID NO: 1) is at least 150 μg. 
     
     
         7 . The pharmaceutical composition according to  claim 2 , wherein the concentration of the at least one CysAβ(33-40) peptide (SEQ ID NO: 1) is from 150 μg to 400 μg. 
     
     
         8 . The pharmaceutical composition according to  claim 2 , wherein the concentration of the at least one CysAβ(33-40) peptide (SEQ ID NO: 1) is from 160 μg to 240 μg. 
     
     
         9 . A glass ampule comprising the pharmaceutical composition of  claim 2 .

Join the waitlist — get patent alerts

Track US2020246430A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.